Table 1 Baseline and clinical characteristics between thymic epithelial tumors and thymic lymphomas
|  | Thymic Epithelial Tumors (n = 80) | Thymic Lymphoma (n = 93) | P-value | ||
|---|---|---|---|---|---|
Age | 50.8 ± 14.8 | 30.3 ± 14.6 | <0.001* | ||
Sex | 49:31 | 52:41 | 0.537 | ||
(Male:Female, n, %) | (61%: 39%) | (56%: 44%) | Â | ||
Initial major symptoms (n, %) | |||||
 B symptom | 4 (5%) | 37 (40%) | <0.001 | ||
 Myasthenia gravis | 6 (8%) | 0 (0%) | 0.009 | ||
 Chest pain | 27 (34%) | 14 (15%) | 0.004 | ||
 Respiratory symptoms | 13 (16%) | 33 (36%) | 0.006 | ||
Pathologic procedure (n, %) | <0.001 | ||||
 Surgery | 28 (35%) | 0 (0%) |  | ||
 Percutaneous biopsy | 52 (65%) | 81 (100%) |  | ||
Histologic type (n, %) | Â | ||||
| Â | Low-risk thymoma | 11 (14%) | Large B-cell lymphoma | 37 (40%) | Â |
Type A thymoma | 1 (1.3%) | Hodgkin lymphoma | 31 (38%) | Â | |
Type AB thymoma | 5 (6.3%) | T lymphoblastic lymphoma | 23 (25%) | Â | |
Type B1 thymoma | 4 (5%) | MALT lymphoma | 1 (1%) | Â | |
Micronodular thymoma | 1 (6.3%) | ALCL lymphoma (ALK+) | 1 (1%) | Â | |
High-risk thymoma (B2, B3) | 17 (21%) | Â | Â | Â | |
Type B2 thymoma | 5 (6%) | Â | Â | Â | |
Type B3 thymoma | 12 (15%) | Â | Â | Â | |
Thymic carcinoma | 44 (55%) | Â | Â | Â | |
Squamous cell carcinoma | 32 (40%) | Â | Â | Â | |
Adenocarcinoma | 4 (5%) | Â | Â | Â | |
Adenosquamous carcinoma | 2 (3%) | Â | Â | Â | |
Sarcomatoid carcinoma | 5 (6%) | Â | Â | Â | |
Mucoepidermoid carcinoma | 1 (1%) | Â | Â | Â | |
Thymic neuroendocrine tumors | 8 (10%) | Â | Â | Â | |
Stage (n, %) | Masaoka Stage | Ann Arbor stage | Â | ||
| Â | I | 19 (24%) | I | 2 (3%) | Â |
II | 8 (10%) | II | 29 (31%) | Â | |
III | 10 (13%) | III | 11 (14%) | Â | |
IV | 43 (53%) | IV | 51 (63%) | Â | |